Skip to main content

Advertisement

SpringerLink
Log in

Surgical Management of Tractional Retinal Detachments in Proliferative Diabetic Retinopathy

  • Diabetic Retinopathy: Medical and Surgical Therapies (Jorge Fortun, Section Editor)
  • Published:
Current Ophthalmology Reports Aims and scope Submit manuscript

Abstract

There have been significant recent advances in the management of diabetic tractional retinal detachments. Pre-operative intravitreal bevacizumab causes regression of active vessels and less intraoperative hemorrhage, small-gauge vitrectomy has dramatically changed how segmentation and delamination are performed, and bimanual surgery and viscodissection offer additional options. Intraoperative bevacizumab may decrease the incidence of postoperative vitreous hemorrhage. Single surgery success rates are generally >85 % with final anatomic success rates approaching 100 %. Useful vision (VA ≥ 20/100) is attained in <40 % of patients in most series while ambulatory vision (VA ≥ 5/200) is attained in <80 % patients in most series. No light perception/light perception only vision occurs in <10 % patients while recurrent hemorrhage occurs in approximately one-third of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Ostri C, Lux A, Lund-Andersen H, la Cour M. Long-term results, prognostic factors, and cataract surgery after diabetic vitrectomy: a 10-year follow-up study. Acta Opthalmol. 2014;92(6):571–6. This is a study investigating the long-term visual and anatomic outcomes of diabetic vitrectomy at a single center. Visual acuity was noted to stabilize at one year following vitrectomy, and vision at 1 year tended to be the best predictor of vision at 5 and 10 years.

  2. Flynn HW, Chew EY, Simons BD, et al. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1992;99:1351–7.

    Article  PubMed  Google Scholar 

  3. Kaiser KS, Maguire MG, Grunwald JE, Lieb D, et al. One-year outcomes of panretinal photocoagulation in proliferative diabetic retinopathy. Am J Ophthalmol. 2000;129:178–85.

    Article  CAS  PubMed  Google Scholar 

  4. • Meleth AD, Carvounis PE. Outcomes of vitrectomy for tractional retinal detachment in diabetic retinopathy. Int Ophthalmol Clin. 2014;54(2):127–39. A great review paper on surgical management, complications, and outcomes of diabetic vitrectomy.

  5. Charles S, Flinn CE. The natural history of diabetic extramacular tractional retinal detachment. Arch Ophthalmol. 1981;99(1):66–8.

    Article  CAS  PubMed  Google Scholar 

  6. Diabetic Retinopathy Vitrectomy Study. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) Report #1. Ophthalmology. 1985;92:492–502.

    Article  Google Scholar 

  7. Yang CM. Surgical treatment for diabetic retinopathy: 5-year experience. J Formos Med Assoc. 1998;97(7):477–84.

    CAS  PubMed  Google Scholar 

  8. Thompson JT, Auer CL, de Bustros S, Michels RG, et al. Prognostic indicators of success and failure in vitrectomy for diabetic retinopathy. Ophthalmology. 1986;93:290–5.

    Article  CAS  PubMed  Google Scholar 

  9. Aaberg TM, Abrams GW. Changing indications and techniques for vitrectomy in management of complications of diabetic retinopathy. Ophthalmology. 1987;94:775–9.

    Article  CAS  PubMed  Google Scholar 

  10. Hwang JC, Sharma AG, Elliott D. Fellow eye vitrectomy for proliferative diabetic retinopathy in an inner city population. Br J Ophthalmol. 2013;97:297–301.

    Article  PubMed  Google Scholar 

  11. Gündüz K, Bakri SJ. Management of proliferative diabetic retinopathy. Compr Ophthalmol Update. 2007;8(5):245–56.

    PubMed  Google Scholar 

  12. Williams DF, Williams GA, Hartz A, Mieler WF, et al. Results of vitrectomy for diabetic traction retinal detachment using the en bloc excision technique. Ophthalmology. 1989;96(6):752–8.

    Article  CAS  PubMed  Google Scholar 

  13. Issa SA, Connor A, Habib M, Steel DH. Comparison of retinal breaks observed during 23 gauge transconjunctival vitrectomy versus conventional 20 gauge surgery for proliferative diabetic retinopathy. Clin Ophthalmol. 2011;20(5):109–14.

    Article  Google Scholar 

  14. Park DH, Shin JP, Kim SY. Comparison of clinical outcomes between 23-gauge and 20-gauge vitrectomy in patients with proliferative diabetic retinopathy. Retina. 2010;30:1662–70.

    Article  PubMed  Google Scholar 

  15. Kumar A, Duraipandi K, Gogia V, Sehra SV, et al. Comparative evaluation of 23- and 25-gauge microincision vitrectomy surgery in management of diabetic macular traction retinal detachment. Eur J Ophthalmol. 2014;24(1):107–13.

    Article  PubMed  Google Scholar 

  16. Altan T, Acar N, Kapran Z, et al. Transconjunctival 25-gauge sutureless vitrectomy and silicone oil injection in diabetic tractional retinal detachment. Retina. 2008;28(9):1201–6.

    Article  PubMed  Google Scholar 

  17. Yamada K, Maeno T, Yamada M. Hybrid microincision vitrectomy surgery combined with 20-gauge silicone cannulas for use with 20-gauge horizontal scissors in diabetic tractional retinal detachment. Clin Ophthalmol. 2013;7:1559–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009;116:927–38.

    Article  PubMed  Google Scholar 

  19. Schoenberger SD, Miller DM, Riemann CD, et al. Outcomes of 25-gauge pars plana vitrectomy in the surgical management of proliferative diabetic retinopathy. Ophthalmol Surg Laser Imaging. 2011;42(6):474–80.

    Article  Google Scholar 

  20. Ozone D, Hirano Y, Ueda J, et al. Outcomes and complications of 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. Ophthalmologica. 2011;226:76–80.

    Article  PubMed  Google Scholar 

  21. Farouk MM, Naito T, Sayed KM, Nagasawa T, et al. Outcomes of 25-gauge vitrectomy for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2011;249(3):369–76.

    Article  PubMed  Google Scholar 

  22. Ovali T, Erkul SO, Ovali C. Spatula microscissor for 23-gauge transconjunctival pars plana vitrectomy in complicated tractional retinal detachment. Retina. 2010;30(5):836–7.

    Article  PubMed  Google Scholar 

  23. Eckardt C. Twin lights: a new chandelier illumination for bimanual surgery. Retina. 2003;23(6):893–4.

    Article  PubMed  Google Scholar 

  24. Moon H, Lee DY, Nam DH. Trimanual technique using assistant-controlled light probe illumination and wide-angle viewing system in 23-gauge sutureless vitrectomy for diabetic tractional retinal detachment. Ophthalmic Surg Lasers Imaging Retina. 2015;46(1):73–6.

    Article  PubMed  Google Scholar 

  25. Wang ZY, Zhang Q, Zhao DS, Zhao PQ. Four-port bimanual vitrectomy in fibrovascular membrane removal. Retina. 2011;31:798–800.

    Article  PubMed  Google Scholar 

  26. Shen LJ, Wang ZY, Qu J, et al. Bimanual technique in proliferative diabetic retinopathy using an optical fiber-free intravitreal surgery system: a case control study. Eur J Ophthalmol. 2009;19:273–9.

    PubMed  Google Scholar 

  27. Awh CC, Rader RS, Walsh AC, de Juan E Jr. A fiberoptic pick-manipulator for vitreoretinal surgery. Arch Ophthalmol. 1994;112:853–4.

    Article  CAS  PubMed  Google Scholar 

  28. Awh CC, Schallen EH, de Juan E Jr. An illuminating laser probe for vitreoretinal surgery. Arch Ophthalmol. 1994;112:553–4.

    Article  CAS  PubMed  Google Scholar 

  29. Steinmetz RL, Grizzard WS, Hammer ME. Vitrectomy for diabetic traction retinal detachment using the multiport illumination system. Ophthalmology. 2002;109:2303–7.

    Article  PubMed  Google Scholar 

  30. Stenkula S, Tornquist R. Healon: a guide to its use in ophthalmic surgery. In: Miller D, Stegman R, editors. Use of Healon in vitrectomy and difficult retinal detachments. New York: Wiley; 1983. p. 207–21.

    Google Scholar 

  31. McLeod D, James CR. Viscodelamination at the vitreoretinal juncture in severe diabetic eye disease. Br J Ophthalmol. 1988;72(6):413–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Grigorian RA, Castellarin A, Fegan R, Seery C, et al. Epiretinal membrane removal in diabetic eyes: comparison of viscodissection with conventional methods of membrane peeling. Br J Ophthalmol. 2003;87:737–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Fortun JA, Hubbard GB 3rd. New viscodissection instrument for use with microincisional vitrectomy in the treatment of diabetic tractional retinal detachments. Arch Ophthalmol. 2011;129(3):352–5.

    Article  PubMed  Google Scholar 

  34. Nadal J, Capella MJ. Treatment of proliferative diabetic retinopathy using viscosurgery with vital dye. Arch Ophthalmol. 2011;129(10):1358–60.

    Article  PubMed  Google Scholar 

  35. Kakehashi A. Total en bloc excision: a modified vitrectomy technique for proliferative diabetic retinopathy. Am J Ophthalmol. 2002;134(5):763–5.

    Article  PubMed  Google Scholar 

  36. Quiroz-Mercado H, Guerrero-Naranjo J, Agurto-Rivera R, Leizaola-Fernández C, et al. Perfluorocarbon-perfused vitrectomy: a new method for vitrectomy: a safety and feasibility study. Graefes Arch Clin Exp Ophthalmol. 2005;243:551–62.

    Article  CAS  PubMed  Google Scholar 

  37. Quiroz-Mercado H, Garcia-Aguirre G, Ustáriz-González O, Martín-Avià J, et al. Perfluorocarbon-perfused vitrectomy using a transconjunctival 25-gauge system. Retina. 2007;27:926–31.

    Article  PubMed  Google Scholar 

  38. Arevalo JF. En bloc perfluorodissection for tractional retinal detachment in proliferative diabetic retinopathy. Ophthalmology. 2008;115:e21–5.

    Article  PubMed  Google Scholar 

  39. Arevalo JF. En bloc perfluorodissection in vitreoretinal surgery: a new surgical technique. Retina. 2008;28:653–6.

    Article  PubMed  Google Scholar 

  40. Arevalo JF, Serrano MA, Arias JD. Perfluorocarbon in vitreoretinal surgery and preoperative bevacizumab in diabetic tractional retinal detachment. World J Diabetes. 2014;5(5):724–9.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Velez-Montoya R, Guerrero-Naranjo JL, Garcia-Aguirre G, Morales-Canton V, et al. Perfluorocarbon-perfused 23 gauge three-dimensional vitrectomy for complicated diabetic tractional retinal detachment. Clin Ophthalmol. 2011;5:1709–15.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Flaxel CJ, Dustin L, Kim J, et al. Outcome of diabetic vitrectomy in Latino population. Retina. 2007;27:1274–8.

    Article  PubMed  Google Scholar 

  43. Yeh PT, Yang CM, Yang CH. Distribution, reabsorption, and complications of preretinal blood under silicone oil after vitrectomy for severe proliferative diabetic retinopathy. Eye. 2012;26:601–8.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Christensen UC, la Cour M. Visual loss after use of intraocular silicone oil associated with thinning of inner retinal layers. Acta Ophthalmol. 2012;90:733–7.

    Article  CAS  PubMed  Google Scholar 

  45. Cazabon S, Groenewald C, Pearce IA, Wong D. Visual loss following removal of intraocular silicone oil. Br J Ophthalmol. 2005;89(7):799–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Herbert EN, Liew SH, Williamson TH. Visual loss after silicone oil removal. Br J Ophthalmol. 2005;89:1667–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Newsom RS, Johnston R, Sullivan P, Aylward B, et al. Visual loss following silicone oil removal. Br J Ophthalmol. 2005;89:1668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Rani PK, Raman R, Bhende P, Sharma T. Visual loss may be due to silicone oil tamponade effect rather than silicone oil removal. Br J Ophthalmol. 2005;89(12):1667.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. McLeod D. Silicone-oil injection during closed microsurgery for diabetic traction retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1986;224:55–9.

    Article  CAS  PubMed  Google Scholar 

  50. Lucke KH, Foerster MH, Laqua H. Long-term results of vitrectomy and silicone oil in 500 cases of complicated retinal detachment. Am J Ophthalmol. 1987;104:624–33.

    Article  CAS  PubMed  Google Scholar 

  51. McLeod D. Silicone oil in diabetic vitrectomy. Br J Ophthalmol. 2003;87:1303–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Tao Y, Jiang YR, Li XX, Gao L, et al. Long-term results of vitrectomy without endotamponade in proliferative diabetic retinopathy with tractional retinal detachment. Retina. 2010;30(3):447–51.

    Article  PubMed  Google Scholar 

  53. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007;114:710–5.

    Article  PubMed  Google Scholar 

  54. Schwatz SD, Alexander R, Hiscott P, Gregor ZJ. Recognition of vitreoschisis in proliferative diabetic retinopathy. A useful landmark in vitrectomy for diabetic traction retinal detachment. Ophthalmology. 1996;103:323–8.

    Article  CAS  PubMed  Google Scholar 

  55. Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1e29.

    Article  Google Scholar 

  56. di Lauro R, De Ruggiero P, di Lauro R, et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:785e91.

    Article  Google Scholar 

  57. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26:699e700.

    Google Scholar 

  58. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695.e1–15.

    Google Scholar 

  59. di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Ophthalmol. 2010;248(6):785–91.

    Article  CAS  Google Scholar 

  60. Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008;246:837–42.

    Article  CAS  PubMed  Google Scholar 

  61. Hernandez-Da Mota SE, Nunez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol. 2010;20:1047–52.

    PubMed  Google Scholar 

  62. Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol. 2009;19:848–52.

    PubMed  Google Scholar 

  63. El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clin Ophthalmol. 2008;2:709–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Pakzad-Vaezi K, Albiani DA, Kirker AW, Merkur AB, et al. A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2014;45:521–4.

    Article  PubMed  Google Scholar 

  65. Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009;116:1943e8.

    Article  Google Scholar 

  66. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2011;5:CD008214.

    PubMed  Google Scholar 

  67. Ahn J, Woo SJ, Chung H, et al. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011;118:2218–26.

    Article  PubMed  Google Scholar 

  68. •• Nicholson BP, Barkmeier AJ. Bevacizumab and diabetic vitrectomy. Int Ophthalmol Clin. 2014;54:111–26. A critical review of literature published on the use of bevacizumab peri-operatively for diabetic vitrectomy, including efficacy, visual outcomes, and complications. Also summarizes research showing the mechanism of action, duration, and timing of vessel regression and fibrosis.

  69. Park DH, Shin JP, Kim SY. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graefes Arch Clin Exp Ophthalmol. 2010;248:641–50.

    Article  CAS  PubMed  Google Scholar 

  70. Cheema RA, Mushtaq J, Al-Khars W, et al. Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage. Retina. 2010;30:1646–50.

    Article  PubMed  Google Scholar 

  71. Van Geest RJ, Lesnik-Oberstein SY, Tan HS, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol. 2012;96:587–90.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Kuiper EJ, van Nieuwenhoven FA, de Smet MD, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One. 2008;3:e2675.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Sohn EH, He S, Kim LA, et al. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1. Arch Ophthalmol. 2012;130:1127–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. El-Sabagh HA, Abdelghaffar W, Labib AM, et al. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology. 2011;118:636–41.

    Article  PubMed  Google Scholar 

  75. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:213e16.

    Article  Google Scholar 

  76. Torres-Soriano ME, Reyna-Castelan E, Hernandez-Rojas M. Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy. Retin Cases Brief Rep. 2009;3(1):70–3.

    Article  PubMed  Google Scholar 

  77. Arevalo JF, Sanchez JG, Lasave AF, Wu L, et al. Intravitreal bevacizumab (Avastin) for diabetic retinopathy: the 2010 GLADAOF lecture. J Ophthalmol. 2011;2011:584238.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Bakri SJ, Snyder MR, Reid JM, Pulido JS, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855–9.

    Article  PubMed  Google Scholar 

  79. Avery RL, Castellarin A, Steinle N, et al. Comparison of systemic pharmacokinetics post anti-VEGF intravitreal injections of ranibizumab, bevacizumab and aflibercept. Abstract presented at the 2013 Annual Meeting of the American Society of Retina Specialists (ASRS); August 24–28; 2013; Toronto, ON.

  80. Zlotcavitch L, Flynn HW Jr, Avery RL, Rachitskaya A. Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy. Clin Ophthalmol. 2015;9:69–71.

    PubMed  PubMed Central  Google Scholar 

  81. Yorston D, Wickham L, Benson S, Bunce C, et al. Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:365–8.

    Article  CAS  PubMed  Google Scholar 

  82. Mason JO III, Colagross CT, Haleman T, Fuller JJ, et al. Visual outcome and risk factors for light perception and no light perception vision after vitrectomy for diabetic retinopathy. Am J Ophthalmol. 2005;140:231–5.

    Article  PubMed  Google Scholar 

  83. Gupta B, Wong R, Sivaprasad S, Williamson TH. Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice. Eye. 2012;26:576–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Thompson JT, De bustros S, Michels RG, et al. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Arch Ophthalmol. 1987;105:497–502.

    Article  CAS  PubMed  Google Scholar 

  85. Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic traction retinal detachment involving the macula. Am J Ophthalmol. 1983;95:22–33.

    Article  CAS  PubMed  Google Scholar 

  86. Nakazawa M, Kimizuka Y, Watabe T, Kato K, et al. Visual outcome after vitrectomy for diabetic retinopathy. A five-year follow-up. Acta Ophthalmol. 1993;71:219–23.

    Article  CAS  Google Scholar 

  87. Shah VA, Brown JS, Mahmoud TH. Correlation of outer retinal microstucture and foveal thickness with visual acuity after pars plana vitrectomy for complications of proliferative diabetic retinopathy. Retina. 2012;32:1775–80.

    Article  PubMed  Google Scholar 

  88. Blankenship GW. Preoperative prognostic factors in diabetic pars plana vitrectomy. Ophthalmology. 1982;89:1246–9.

    Article  CAS  PubMed  Google Scholar 

  89. Lee DY, Jeong HS, Sohn HJ, et al. Combined 23-gauge sutureless vitrectomy and clear corneal phacoemulsification in patients with proliferative diabetic retinopathy. Retina. 2011;31:1753–8.

    Article  PubMed  Google Scholar 

  90. Zhao LQ, Zhu H, Zhao PQ, et al. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol. 2011;95:1216–22.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Gupta B, Sivaprasad S, Wong R, et al. Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: the DRIVE UK study. Eye. 2012;26:510–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Tolentino FI, Freeman HM, Tolentino FL. Closed vitrectomy in the management of diabetic traction retinal detachment. Ophthalmology. 1980;87:1078–80.

    Article  CAS  PubMed  Google Scholar 

  93. Canny CLB, O’Hanley GP, Wells GA. Pars plana vitrectomy for the complications of diabetic retinopathy: a report on 131 cases. Can J Ophthalmol. 1985;20:11–5.

    CAS  PubMed  Google Scholar 

  94. Meier P, Wiedemann P. Vitrectomy for traction macular detachment in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 1997;235:569–74.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alkek Eye Center, Cullen Eye Institute, Baylor College of Medicine, 1977 Butler Blvd, Houston, TX, 77030, USA

    Nora Khatib & Petros E. Carvounis

Authors
  1. Nora Khatib
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Petros E. Carvounis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petros E. Carvounis.

Ethics declarations

Disclosure

Dr. Nora Khatib and Dr. Petros Carvounis declare that they have no conflict of interest.

Additional information

This article is part of the Topical Collection on Diabetic Retinopathy: Medical and Surgical Therapies.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khatib, N., Carvounis, P.E. Surgical Management of Tractional Retinal Detachments in Proliferative Diabetic Retinopathy. Curr Ophthalmol Rep 4, 75–83 (2016). https://doi.org/10.1007/s40135-016-0096-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40135-016-0096-x

Keywords

Search

Navigation